References
- Zhang E, Xing R, Liu S, et al. Current advances in development of new docetaxel formulations. Expert Opin Drug Deliv. 2019;16(3):301–312.
- World Intellectual Property Organization. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof. Publication No. WO/2008/127358. Available from: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2008127358&redirectedID=true.
- Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol. 2010;624:25–37.
- McKeage K. Nanosomal docetaxel lipid suspension: a guide to its use in cancer. Clin Drug Investig. 2017;37(4):405–410.
- Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol. 2006;24(31):4963–4970.
- Ahmad A, Sheikh S, Ali SM, et al. Development of aqueous based formulation of docetaxel: safety and pharmacokinetics in patients with advanced solid tumors. J Nanomed Nanotechnol. 2015;6(3):1.
- Lewis LD, Miller AA, Rosner GL, et al. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007;13(11):3302–3311.
- Ahmad A, Sheikh S, Taran R, et al. Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients. Clin Breast Cancer. 2014;14(3):177–181.
- Ashraf QM, Sajad QR, Khan MA, et al. Efficacy and safety of a novel nanosomal docetaxel lipid suspension as an anticancer agent – a retrospective study. J Cancer Oncol. 2018;2(4):000132.
- Murali A, Gupta S, Pendharkar. D. Efficacy and tolerability of nanoparticle docetaxel lipid suspension. J Clin Oncol. 2018;36(15_suppl):e14542–e14542.
- Vyas V, Joshi N, Khan. M. Novel docetaxel formulation (NDLS) in low cardiac reserve ovarian cancer. Open Access J Cancer Oncol. 2018;2(2):000122.
- Gupta S, Pawar SS, Bunger. D. Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery. BMJ Case Rep. 2017;2017:bcr2017220686.
- Naik R, Khan. MA. Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: a case report. Mol Clin Oncol. 2017;6(3):341–343.
- Prasanna R, Bunger D, Khan. MA. Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: a case report. Mol Clin Oncol. 2018;8(2):296–299.
- Rajappa S, Joshi A, Doval DC, et al. Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer. Oncol Lett. 2018;16(3):3757–3769.